This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
by Zacks Equity Research
Haemonetics' (HAE) share price is likely to grow, backed by solid business performance across all its segments.
Charles River (CRL) Gains From Global Demand Amid FX Woes
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.
Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe
by Zacks Equity Research
Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.
LivaNova (LIVN) Advances Cardiopulmonary Wing With Essenz ILBM
by Zacks Equity Research
LivaNova's (LIVN) Essenz ILBM boasts B-Capta sensing technology, ensuring accuracy and compliance with Clinical Laboratory Improvement Amendments.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
A diversified product portfolio and a broad geographic footprint bode well for Teleflex (TFX).
Globus Medical (GMED) Completes NuVasive Merger Agreement
by Zacks Equity Research
Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.
ICU Medical's (ICUI) Plum Duo With Safety Shield Gets 510(k) Nod
by Zacks Equity Research
The Plum Duo infusion pump represents the latest addition to ICU Medical's (ICUI) advanced lineup of infusion devices.
Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool
by Zacks Equity Research
Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.
Boston Scientific's (BSX) FARAPULSE System Study Data Positive
by Zacks Equity Research
Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.
Quest Diagnostics' (DGX) AAV Test Gets FDA's Breakthrough Nod
by Zacks Equity Research
Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.
Walgreens (WBA) OTC NARCAN Nasal Spray to be Available Soon
by Zacks Equity Research
Walgreens (WBA) is instructing Americans to administer this life-saving drug that, if given in time, can reverse the effects of an opioid overdose.
Abbott's (ABT) Libre Gains Momentum Amid Low Testing Sales
by Zacks Equity Research
Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
Inspira (IINN) Advances Foothold in Europe With Extended Deal
by Zacks Equity Research
The extended service agreement complements a previously announced strategic agreement between Inspira (IINN) and Innovimed.
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integra (IART) based on the prospects of its CSS segment and a stable liquidity position.
Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH
by Zacks Equity Research
Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on recent product launches.
STERIS (STE) Banks on New Pact for Growth Amid Rising Expenses
by Zacks Equity Research
Continuous procedure volume growth in the United States, favorable pricing and market share gains are driving STERIS' (STE) Healthcare segment organic growth.
Haemonetics (HAE) Expands VASCADE System Portfolio in Germany
by Zacks Equity Research
Haemonetics (HAE) announces the first treatment of patients in Germany with the VASCADE MVP Venous Vascular Closure system.
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) due to innovative new product launches and solid execution.
Insulet (PODD) Launches Omnipod 5 AID System in Germany
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 is available in the United States and the United Kingdom.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), led by the strength of its dental business.
Orthofix's (OFIX) New Launch to Benefit the MIS Spine Market
by Zacks Equity Research
Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0.
Syneos Health (SYNH) Expands Catalyst Site Program to China
by Zacks Equity Research
Syneos Health (SYNH) announces a collaboration with China's Wuhan Union Hospital, expanding clinical trial capabilities.
Integra (IART) CSS Sales Aid, Boston Recall Hurts Growth
by Zacks Equity Research
In spite of facing foreign exchange fluctuations across its non-U.S. business, Integra (IART) is successfully broadening its international footprint.